Finance

Lists
Q2 2026 earnings • released • EPS beat +25,66% • Revenue beat +5,33%
See results
ONC:NASDAQ
BeOne Medicines AG
348,27 USD
+5,60%
(+18,47) 1D
7-авг., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONC...
Open
345,47 USD
High
349,88 USD
Low
341,86 USD
Mkt. cap
43,31 млд
Avg. vol.
361,62 миң
Volume
638,20 миң
52-wk high
385,22 USD
52-wk low
253,95 USD
Beta
0,49
Shares outstanding
109,79 млн
No. of employees
12 миң
Open
345,47 USD
High
349,88 USD
Low
341,86 USD
Mkt. cap
43,31 млд
Avg. vol.
361,62 миң
Volume
638,20 миң
52-wk high
385,22 USD
52-wk low
253,95 USD
Beta
0,49
Shares outstanding
109,79 млн
No. of employees
12 миң
News stories
From sources across the web
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 миң
Founded2010-ж., 28-окт.
Headquarters-
Sector-
Websitebeonemedicines.com
Analyst ratings
Based on 15 analysts giving stock ratings to ONC in the past 3 months
Strong buy
Buy
15
Hold
0
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for ONC in the last 3 months.
Highest
Current 348,27 USD
466,00 USD (+33,80%)
Average
414,15 USD (+18,92%)
Lowest
340,00 USD (-2,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jill Wu
CMB International Securities
Buy
Maintained
442,31 USD
+27%
08/07/2026
David Li
Bank of America Securities
Buy
Reiterated
423,00 USD
+21,5%
08/06/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
400,00 USD
+14,9%
08/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
430,00 USD
+23,5%
08/05/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
450,00 USD
+29,2%
08/05/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
466,00 USD
+33,8%
08/06/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
405,00 USD
+16,3%
08/06/2026
Etzer Darout
Barclays
Buy
Maintained
407,00 USD
+16,9%
08/06/2026
Yaron Werber
TD Cowen
Buy
Maintained
454,00 USD
+30,4%
08/05/2026
Gregory Renza
Truist Financial
Buy
Reiterated
418,00 USD
+20%
08/06/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
405,00 USD
+16,3%
08/06/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
425,00 USD
+22%
07/23/2026
Faisal Khurshid
Jefferies
Buy
Upgraded
380,00 USD
+9,1%
07/12/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
340,00 USD
-2,4%
07/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
415,00 USD
+19,2%
05/20/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
367,00 USD
+5,4%
05/15/2026
Rebecca Liang
Bernstein
Buy
Maintained
412,00 USD
+18,3%
03/18/2026
Last report
2026-ж., 5-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
2,05 USD / 1,63 USD
+25,66%beat
Revenue / Est. (USD)
1,71 млд / 1,62 млд
+5,33%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,41 млд
1,50 млд
1,51 млд
1,71 млд
Cost of goods sold
196,51 млн
142,42 млн
167,22 млн
174,53 млн
Cost of revenue
196,51 млн
142,42 млн
167,22 млн
174,53 млн
Research and development expenses
523,66 млн
615,42 млн
541,22 млн
612,28 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
529,00 млн
555,29 млн
555,10 млн
593,21 млн
Operating expense
1,05 млд
1,17 млд
1,10 млд
1,21 млд
Total operating expenses
1,25 млд
1,31 млд
1,26 млд
1,38 млд
Operating income
163,11 млн
185,04 млн
249,90 млн
325,05 млн
Other non operating income
-4,76 млн
4,16 млн
14,54 млн
-2,68 млн
EBT including unusual items
147,16 млн
149,24 млн
259,22 млн
312,46 млн
EBT excluding unusual items
160,80 млн
189,96 млн
259,22 млн
309,33 млн
Income tax expense
22,32 млн
82,74 млн
31,86 млн
75,45 млн
Effective tax rate
15,17%
55,44%
12,29%
24,15%
Other operating expenses
-
-
-
-
Net income
124,84 млн
66,50 млн
227,36 млн
237,01 млн
Net profit margin
8,84%
4,44%
15,02%
13,90%
Earnings per share
1,09
0,58
1,96
2,05
Interest and investment income
13,79 млн
32,37 млн
27,66 млн
27,90 млн
Interest expense
-10,76 млн
-32,47 млн
-32,89 млн
-39,74 млн
Net interest expenses
3,03 млн
-103,00 миң
-5,22 млн
-11,84 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
198,86 млн
219,47 млн
289,30 млн
363,97 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору